TScan Therapeutics, Inc (TCRX) IPO Opens 20% Lower

Today's IPO for TScan Therapeutics, Inc (NYSE: TCRX) opened for trading at $12 after pricing 6,666,667 shares of common stock at a public offering price of $15.00 per share.

Morgan Stanley, Jefferies, Cowen and Barclays are acting as Joint Book-running Managers for the offering.

TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

You May Also Be Interested In

• Columbus Circle Capital Corp III prices $200M IPO on Nasdaq
• SK Hynix eyes blockbuster US debut with $149 ADR target, Bloomberg reports
• Viking Acquisition Corp. II raises $230 million in NYSE IPO